APO 010

Drug Profile

APO 010

Alternative Names: APO010

Latest Information Update: 27 Mar 2017

Price : $50

At a glance

  • Originator Apoxis
  • Developer Onxeo SA
  • Class Antineoplastics; Recombinant fusion proteins; Tumour necrosis factors
  • Mechanism of Action Apoptosis stimulants; CD95 antigen stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Haematological malignancies

Most Recent Events

  • 21 Mar 2017 Oncology Venture plans a phase I/II trial for Multiple myeloma in Denmark
  • 21 Mar 2017 The Danish Medicines Agency approves a Clinical Trial Application APO 010 in Multiple Myeloma
  • 31 Jan 2017 Oncology Venture files Clinical Trial Application with the Danish Medicine Agency for Multiple Myeloma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top